• Arturo Abundes-Velasco, Jorge Padilla-Ibarra, Gian M Jiménez-Rodríguez, Julio I Farjat-Pasos, Eduardo A Arias-Sánchez, Félix Damas-de Los Santos, Marco A Martínez-Ríos, Francisco J Molina-Méndez, Tomás E Sánchez-Pérez, Marco M Arai-Ito, Sebastián Aceves-Díaz González, David A Rodríguez-Parra, Alberto Aranda-Fraustro, Felipe A Masso-Rojas, Ramsés Galaz-Méndez, and Marco A Peña-Duque.
• Instituto Nacional de Cardiología "Ignacio Chávez", Desarrollo e Innovación Tecnológica, Ciudad de México, México.
• Gac Med Mex. 2020 Jan 1; 156 (4): 279-285.

IntroductionA drug-eluting coronary stent is being developed at the National Institute of Cardiology of Mexico for the treatment of ischemic heart disease.ObjectiveTo establish the best animal model for the tests, to show the advances in the drug-eluting stent prototype, to assess two drugs' antiproliferative activity and histological results.MethodSmooth muscle cell culture tests were performed in order to assess sirolimus and paclitaxel antiproliferative properties. The drugs were encapsulated inside the polymeric matrix of the stents. Rabbits and pigs were used as animal models.ResultsSirolimus and paclitaxel showed an inhibitory effect, which was higher for the latter. Infrared spectroscopy and light and optical microscopy showed that the drug/polymer layer properly adhered to the stent. At a four-week follow-up, both animal models showed satisfactory clinical evolution and adequate histological response, although the porcine model was shown to be more suitable for future protocols.ConclusionsPreliminary tests of the drug-eluting stent provided bases for the development of a study protocol with an adequate number of pigs and with clinical angiographic and histopathological three-month follow-up.Copyright: © 2020 Permanyer.

21 keywords...

hide…